文献速递儿科与产科急症呼吸衰竭与机械通气重症综合管理与镇静镇痛

四例危重儿科COVID-19患者接受恢复期血浆治疗的病例系列

Convalescent Plasma Therapy in Four Critically Ill Pediatric Patients With Coronavirus Disease 2019: A Case Series.
PubMed 文献 · Crit Care Explor · 2020-10-01
一句话结论四例危重儿科COVID-19急性呼吸衰竭患者在接受恢复期血浆后均完全康复出院,未发生输注相关不良事件,但需临床试验验证安全性和有效性。

本文报告四例危重儿科COVID-19患者(年龄5至16岁),均因急性呼吸衰竭接受COVID-19恢复期血浆治疗,并在住院后26小时内输注。所有患者同时使用了其他疾病调节药物,最终均完全康复、脱离氧疗出院,恢复期血浆输注未发生不良事件。作者认为恢复期血浆对危重儿科COVID-19患者是可行疗法,但需设计良好的临床试验确定总体安全性和有效性。

要点

  • 四例危重儿科COVID-19患者(5-16岁)均在住院26小时内接受恢复期血浆,全部完全康复出院并脱离氧疗。
  • 恢复期血浆输注未发生任何不良事件。
  • 所有患者同时使用了其他疾病调节药物,无法单独归因于恢复期血浆的疗效。
  • 恢复期血浆对危重儿科COVID-19患者是可行疗法,但总体安全性和有效性需临床试验确定。

适用人群与场景

  • 危重儿科COVID-19患者,年龄5至16岁,表现为急性呼吸衰竭,接受恢复期血浆作为重症治疗策略。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 在住院后26小时内输注COVID-19恢复期血浆;所有患者同时使用了其他疾病调节药物(原文未提及具体药名、剂量、途径或频次)。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 病例系列,四例危重儿科COVID-19急性呼吸衰竭患者,年龄5至16岁;全部在住院26小时内接受恢复期血浆并同时使用其他疾病调节药物;全部完全康复、脱离氧疗出院;恢复期血浆输注未发生不良事件。

证据类型、等级与局限

  • 病例系列;原文未给出证据等级或推荐强度;原文明确述局限性:样本量小(四例)、缺乏对照、同时使用其他疾病调节药物、需设计良好的临床试验确定总体安全性和有效性。

对床旁实践的改变

  • 原文提示恢复期血浆对危重儿科COVID-19患者是可行疗法,但证据来自四例病例系列,不能据此改变常规实践;适用人群为危重儿科COVID-19急性呼吸衰竭患者;原文无法单独评估恢复期血浆的疗效,因所有患者同时使用了其他疾病调节药物。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

UNLABELLED: Coronavirus disease 2019 is a pandemic with no specific therapeutic agents or vaccination. Small published case series on critically ill adults suggest improvements in clinical status with minimal adverse events when patients receive coronavirus disease 2019 convalescent plasma, but data on critically ill pediatric patients are lacking. We report a series of four critically ill pediatric patients with acute respiratory failure who received coronavirus disease 2019 convalescent plasma as a treatment strategy for severe disease.

CASE SUMMARY: Patients ranged in age from 5 to 16 years old. All patients received coronavirus disease 2019 convalescent plasma within the first 26 hours of hospitalization. Additional disease modifying agents were also used. All patients made a full recovery and were discharged home off of oxygen support. No adverse events occurred from the coronavirus disease 2019 convalescent plasma transfusions.

CONCLUSION: Coronavirus disease 2019 convalescent plasma is a feasible therapy for critically ill pediatric patients infected with severe acute respiratory syndrome coronavirus 2. Well-designed clinical trials are necessary to determine overall safety and efficacy of coronavirus disease 2019 convalescent plasma and additional treatment modalities in pediatric patients.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Schwartz SP, Thompson P, Smith M, et al. Convalescent Plasma Therapy in Four Critically Ill Pediatric Patients With Coronavirus Disease 2019: A Case Series. Crit Care Explor. 2020. PMID: 33063037. doi:10.1097/CCE.0000000000000237

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。